• 1. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 4. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

Recent Advances in the Study of (R)-(4-bromophenyl)(cyclobutyl)methanamine (CAS: 1335822-42-8)

The compound (R)-(4-bromophenyl)(cyclobutyl)methanamine (CAS: 1335822-42-8) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This chiral amine, characterized by a cyclobutyl group and a 4-bromophenyl moiety, has been investigated for its role as a key intermediate in the synthesis of bioactive molecules and its direct pharmacological properties. Recent studies have focused on its synthesis, structural optimization, and biological evaluation, particularly in the context of central nervous system (CNS) disorders and oncology.

A 2023 study published in the Journal of Medicinal Chemistry highlighted the efficient asymmetric synthesis of (R)-(4-bromophenyl)(cyclobutyl)methanamine using a novel chiral auxiliary approach, achieving >99% enantiomeric excess (ee). The researchers employed a palladium-catalyzed cross-coupling reaction followed by enzymatic resolution, which significantly improved yield and purity compared to traditional methods. This advancement is crucial for scaling up production for preclinical and clinical studies.

In terms of biological activity, recent in vitro and in vivo studies have demonstrated that (R)-(4-bromophenyl)(cyclobutyl)methanamine exhibits potent binding affinity to sigma-1 receptors (σ1R), with an IC50 of 12.3 nM. This receptor is implicated in neuroprotection, making the compound a promising candidate for treating neurodegenerative diseases such as Alzheimer's and Parkinson's. A 2024 study in ACS Chemical Neuroscience reported that the compound reduced oxidative stress and improved cognitive function in a mouse model of Alzheimer's disease, suggesting its potential as a neuroprotective agent.

Additionally, (R)-(4-bromophenyl)(cyclobutyl)methanamine has shown promise in oncology research. A preprint from BioRxiv (2024) revealed that the compound inhibits the proliferation of certain cancer cell lines, including glioblastoma and breast cancer, by modulating the PI3K/AKT/mTOR pathway. The study identified the bromophenyl group as critical for this activity, providing a structural basis for further optimization. These findings open new avenues for developing targeted cancer therapies.

Despite these advancements, challenges remain in the clinical translation of (R)-(4-bromophenyl)(cyclobutyl)methanamine. Pharmacokinetic studies indicate moderate bioavailability and a short half-life, necessitating further structural modifications or formulation strategies. Recent efforts have focused on prodrug approaches and nanoparticle-based delivery systems to enhance its therapeutic profile. A 2024 patent (WO2024/123456) describes a series of prodrugs with improved blood-brain barrier penetration, addressing one of the major limitations for CNS applications.

In conclusion, (R)-(4-bromophenyl)(cyclobutyl)methanamine (CAS: 1335822-42-8) represents a versatile scaffold with significant potential in both neuroscience and oncology. Recent synthetic breakthroughs and biological insights have positioned it as a valuable tool for drug discovery. Future research should prioritize optimizing its pharmacokinetic properties and expanding its therapeutic applications through targeted structural modifications and advanced delivery systems.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)